TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6419594

Group type: EXPERIMENTAL
Intervention: 1 mg auranofin daily
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 9 mg auranofin daily
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 2 mg auranofin daily
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 6 mg auranofin daily
Number of subjects: 2
Study: 28912054

Group type: EXPERIMENTAL
Intervention: Pharmacist interventions including patient, laboratory, and individualized CV risk assessments; treatment recommendations; prescription adaptations; and regular monthly follow-up for 3 months.
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Pharmacist interventions
Number of subjects: 290
Study: 26718805

Group type: EXPERIMENTAL
Intervention: Technosphere inhaled insulin (TI) during URTI
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Technosphere inhaled insulin (TI) during meal challenges
Number of subjects: 20
Study: 25764287

Group type: EXPERIMENTAL
Intervention: Low ligation of the inferior mesenteric artery (IMA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: High ligation of the inferior mesenteric artery (IMA)
Number of subjects: 100
Study: 23597262

Group type: EXPERIMENTAL
Intervention: Intensive E-mail based intervention
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Brief advice on smoking cessation (Control)
Number of subjects: 1060
Study: 20538951

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18537977

Group type: EXPERIMENTAL
Intervention: Presence of HLA-DR15
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Presence of PNH-type cells
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Presence of anti-PMS1 antibody
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no HLA-DR15, no PNH-type cells, no anti-PMS1 antibody)
Number of subjects: 103
Study: 17767017

Group type: EXPERIMENTAL
Intervention: Leukocyte therapy (immunization by isolated lymphocytes from husbands, 50 to 100 million washed and resuspended mononuclear cells injected by I.V., S.C., and I.D. route, repeated immunization if needed)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (81 age‐matched non‐pregnant RSA women, not immunized)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Leukocyte therapy in primary aborters
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Leukocyte therapy in secondary aborters
Number of subjects: 92
Study: 14631611

Group type: EXPERIMENTAL
Intervention: Active-comparator trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-controlled trials
Number of subjects: 0
Study: 10894866

Group type: COMPARATOR
Intervention: Standard-dose regimen (arm A): doxorubicin (50 mg/m² on day 1) and ifosfamide (5 g/m² on day 1)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Intensified regimen (arm B): doxorubicin (75 mg/m² on day 1), ifosfamide (5 g/m² on day 1), and rhGM-CSF (250 microgram/m² on days 3 to 16)
Number of subjects: 314
Study: 8625677

Group type: EXPERIMENTAL
Intervention: Heliox (70% helium:30% oxygen)
Number of subjects: 11
Study: 1612959

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (pH 7.3)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Unbuffered lidocaine (pH 6.5)
Number of subjects: 54
Study: 6139040

Group type: EXPERIMENTAL
Intervention: dexchlorpheniramine maleate sustained release tablets (6 mg b.d.)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: budesonide nasal spray (200 micrograms b.d.)
Number of subjects: 61
Study: 30868672

Group type: EXPERIMENTAL
Intervention: Conventional PDT (Aktilite®, 630 nm, 37 J/cm2, 8 min)
Number of subjects: 774

Group type: COMPARATOR
Intervention: Half-time PDT (Aktilite®, 630 nm, 37 J/cm2, 4 min)
Number of subjects: 774

Group type: COMPARATOR
Intervention: Half-time PDT
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Conventional PDT
Number of subjects: 774
Study: 29787486

Group type: EXPERIMENTAL
Intervention: Perceptual learning with random dot stimuli (RDS) in the form of a computer video game
Number of subjects: 32
Study: 27777180

Group type: EXPERIMENTAL
Intervention: Daily inhaled corticosteroids (ICSs)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Daily leukotriene receptor antagonists
Number of subjects: 300

Group type: COMPARATOR
Intervention: As-needed ICS treatment coadministered with albuterol
Number of subjects: 300
Study: 24667440

Group type: EXPERIMENTAL
Intervention: infliximab (INX)
Number of subjects: 429

Group type: COMPARATOR
Intervention: etanercept
Number of subjects: 429

Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 429
Study: 22323300

Group type: EXPERIMENTAL
Intervention: Surgical face masks worn by patients with MDR-TB
Number of subjects: 17

Group type: COMPARATOR
Intervention: No surgical face masks worn by patients with MDR-TB (control group)
Number of subjects: 17
Study: 19021920

Group type: EXPERIMENTAL
Intervention: Organically produced carrots (200 g/d; 2 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Conventionally produced carrots (200 g/d; 2 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No carrots (control group)
Number of subjects: 36
Study: 17583105

Group type: EXPERIMENTAL
Intervention: cetirizine hydrochloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 15140462

Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation program
Number of subjects: 0
Study: 11784874

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin
Number of subjects: 154

Group type: COMPARATOR
Intervention: Etoposide plus cisplatin
Number of subjects: 154
Study: 9817267

Group type: EXPERIMENTAL
Intervention: Epirubicin (cumulative doses greater than 950 mg/m2)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Previous irradiation against the heart
Number of subjects: 469
Study: 8079617

Group type: EXPERIMENTAL
Intervention: Primary argon laser trabeculoplasty
Number of subjects: 82

Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 82
Study: 2491827

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Misoprostol 100 micrograms
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 984241

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 31539053

Group type: EXPERIMENTAL
Intervention: 3-month controlled diet and supervised exercise program
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cycles with LPDs
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Decrease in LH pulse frequency
Number of subjects: 14
Study: 31118140

Group type: EXPERIMENTAL
Intervention: Trametinib and GSK2141795
Number of subjects: 14
Study: 28647012

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 36
Study: 25955227

Group type: EXPERIMENTAL
Intervention: Levothyroxine (L-T4) treatment for 6 months
Number of subjects: 41
Study: 23676807

Group type: EXPERIMENTAL
Intervention: Transanal haemorrhoidal dearterialisation with mucopexy (THD)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Stapler haemorrhoidopexy (SH)
Number of subjects: 124
Study: 21828236

Group type: EXPERIMENTAL
Intervention: Surfactant protein-D (SP-D) levels
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Krebs von Lungren-6 (KL-6) levels
Number of subjects: 1264

Group type: COMPARATOR
Intervention: SP-D levels among controls with CXR scarring
Number of subjects: 1264

Group type: COMPARATOR
Intervention: KL-6 levels among controls with CXR scarring
Number of subjects: 1264
Study: 19212272

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 0
Study: 17685736

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75 mg/day to 300 mg/day)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 14717655

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (2.7 mmol/l)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normoglycaemia (4.7 mmol/l)
Number of subjects: 15
Study: 11591895

Group type: EXPERIMENTAL
Intervention: Once-daily administration of gentamicin (6.5 mg/kg starting dose, adjusted to 7.3 mg/kg per day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Multiple-daily administration of gentamicin (6.8 mg/kg per day)
Number of subjects: 52
Study: 9711100

Group type: EXPERIMENTAL
Intervention: Exercise test after myocardial infarction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative exercise test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive exercise test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine postinfarction exercise test
Number of subjects: 0
Study: 7992810

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of Tc-99m pertechnetate at acupuncture point K-3 (Taixi)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Subcutaneous injection of Tc-99m pertechnetate at other acupuncture points (APs)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Subcutaneous injection of Tc-99m pertechnetate at non-acupuncture points (NAPs)
Number of subjects: 157
Study: 2659954

Group type: EXPERIMENTAL
Intervention: Org OD 14 (new steroid drug taken orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Org OD 14
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30924265

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) for 12 weeks, three times a week.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care alone (control group).
Number of subjects: 66
Study: 28497899

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: LAAO devices
Number of subjects: 263
Study: 26202811

Group type: EXPERIMENTAL
Intervention: Alteplase plus oral fingolimod 0.5 mg daily for 3 consecutive days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Alteplase alone
Number of subjects: 25
Study: 22841937

Group type: EXPERIMENTAL
Intervention: RapidArc (Volumetric-modulated arc therapy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fixed-field IMRT (Intensity-modulated radiotherapy)
Number of subjects: 20
Study: 22028623

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with gemcitabine and bevacizumab
Number of subjects: 20
Study: 19455550

Group type: EXPERIMENTAL
Intervention: Robotic surgery (ROB)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Laparotomy (LAP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Laparoscopy (LSC)
Number of subjects: 65
Study: 16445555

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Combined CM and CBT
Number of subjects: 171
Study: 14519887

Group type: COMPARATOR
Intervention: CarboStent (C; n = 168)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Stainless-steel stent (S; n = 161)
Number of subjects: 329
Study: 12382151

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 2.0 g/kg given over 24 or 48 hours
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 22
Study: 9651568

Group type: EXPERIMENTAL
Intervention: Acipimox (3 X 250 mg daily for 12 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acipimox (3 X 250 mg daily for 12 weeks) in a subgroup of 8 patients with baseline TG > 4 mmol L-1
Number of subjects: 18
Study: 7543955

Group type: EXPERIMENTAL
Intervention: rG.CSF (5 micrograms/kg/d, d.i.v.)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control (non-treated group)
Number of subjects: 95
Study: 2539830

Group type: EXPERIMENTAL
Intervention: Cod liver oil (CLO) supplementation (25 ml daily for 8 weeks)
Number of subjects: 40
Study: 368817

Group type: EXPERIMENTAL
Intervention: 75 mg of chlorpromazine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 75 mg of amitriptyline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg of diazepam
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 18 mg of dextroamphetamine sulfate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30122055

Group type: EXPERIMENTAL
Intervention: Financial incentives for class attendance and weight loss
Number of subjects: 1595

Group type: COMPARATOR
Intervention: Financial incentives for class attendance only
Number of subjects: 1595
Study: 28439716

Group type: EXPERIMENTAL
Intervention: First-generation antipsychotic drugs
Number of subjects: 111346

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic drugs
Number of subjects: 111346
Study: 25273886

Group type: EXPERIMENTAL
Intervention: None/Trace PVR
Number of subjects: 2434

Group type: EXPERIMENTAL
Intervention: Mild PVR
Number of subjects: 2434

Group type: EXPERIMENTAL
Intervention: Moderate/Severe PVR
Number of subjects: 2434
Study: 23102531

Group type: EXPERIMENTAL
Intervention: Aggressive fever control strategy (acetaminophen, physical cooling); acetaminophen dose: 2275 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Permissive fever control strategy; acetaminophen dose: 0 mg
Number of subjects: 200
Study: 22132651

Group type: EXPERIMENTAL
Intervention: Combined VHA/VHB vaccine (HAB group)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Concomitant VHA and VHB vaccines (ENG+HAV group)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Concomitant VHA and VHB vaccines (HBVX+VAQ group)
Number of subjects: 596
Study: 19368782

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated subunit influenza vaccine Influvac®
Number of subjects: 6415
Study: 16344276

Group type: EXPERIMENTAL
Intervention: Booklet about chemotherapy (n = 72)
Number of subjects: 145

Group type: COMPARATOR
Intervention: No booklet (Control group, n = 73)
Number of subjects: 145
Study: 15292765

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Number of subjects: 222

Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation
Number of subjects: 222
Study: 11533336

Group type: EXPERIMENTAL
Intervention: Variable-flow NCPAP
Number of subjects: 24

Group type: COMPARATOR
Intervention: Constant-flow NCPAP
Number of subjects: 24
Study: 9032742

Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg
Number of subjects: 437

Group type: COMPARATOR
Intervention: 17 beta‐estradiol 2 mg plus norethisterone acetate 1 mg
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: tibolone
Number of subjects: 437
Study: 8060436

Group type: EXPERIMENTAL
Intervention: Albuterol powder 200 micrograms inhaled every 4 hours (Group I)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Albuterol nebulized solution 2.5 mg inhaled every 4 hours (Group II)
Number of subjects: 15
Study: 30859944

Group type: EXPERIMENTAL
Intervention: Brexpiprazole (flexible-dose 1-4mg/day)
Number of subjects: 187
Study: 28449955

Group type: EXPERIMENTAL
Intervention: Oral naltrexone
Number of subjects: 144

Group type: COMPARATOR
Intervention: No oral naltrexone (7-day washout period)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Legal status (not on parole or probation)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Recent opioid detoxification type (longer-term detoxification program)
Number of subjects: 144
Study: 26284539

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nonresponders (no treatment intervention specified)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: IL28B CC genotype
Number of subjects: 38
Study: 25098489

Group type: EXPERIMENTAL
Intervention: Synbiotic [Lactobacillus acidophilus NCFM (10(9) CFU) and cellobiose (5 g)]
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 23134997

Group type: EXPERIMENTAL
Intervention: Lidocaine diluted with normal saline (3 mL of 1% lidocaine + epinephrine in 30 mL of bacteriostatic 0.9% sodium chloride in a 1:10 ratio)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Buffered lidocaine (5 mL of 8.4% sodium bicarbonate solution and 50 mL of 1% lidocaine + epinephrine in a 1:10 ratio)
Number of subjects: 31
Study: 19665403

Group type: EXPERIMENTAL
Intervention: Advice and exercise plus true or non-penetrating acupuncture
Number of subjects: 352

Group type: COMPARATOR
Intervention: Advice and exercise
Number of subjects: 352
Study: 17804079

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Solution-focused therapy
Number of subjects: 326

Group type: COMPARATOR
Intervention: Long-term psychodynamic psychotherapy
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: All therapies (short-term and long-term)
Number of subjects: 326
Study: 15754410

Group type: EXPERIMENTAL
Intervention: Fermented soy milk
Number of subjects: 28

Group type: COMPARATOR
Intervention: Regular soy milk
Number of subjects: 28
Study: 14574055

Group type: EXPERIMENTAL
Intervention: BNP-guided treatment
Number of subjects: 69

Group type: COMPARATOR
Intervention: Clinical score treatment (Control)
Number of subjects: 69
Study: 10589358

Group type: EXPERIMENTAL
Intervention: Triple combination therapy with hydroxychloroquine, sulfasalazine, and methotrexate (MTX)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 50
Study: 8933780

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate, 200 micrograms once daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1805294

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day PO)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 21
Study: 6425713

Group type: EXPERIMENTAL
Intervention: l-tryptophan (40 mg/kg body weight)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: l-tryptophan
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30652930

Group type: EXPERIMENTAL
Intervention: Home based strength-training program
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Group exercise program followed by automated telephone calls
Number of subjects: 25
Study: 31227374

Group type: EXPERIMENTAL
Intervention: Septoplasty with or without concurrent turbinate surgery
Number of subjects: 203

Group type: COMPARATOR
Intervention: Non-surgical management
Number of subjects: 203
Study: 29698106

Group type: EXPERIMENTAL
Intervention: 40 mg of MS-Contin (morphine)
Number of subjects: 21
Study: 26593548

Group type: EXPERIMENTAL
Intervention: RBCC
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RBCC+beef
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: heme+fish
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: heme+chicken
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: heme+beef
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: casein, collagen, albumin
Number of subjects: 45

Group type: COMPARATOR
Intervention: heme alone
Number of subjects: 45
Study: 25041494

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg in 50 ml infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg in 250 ml infusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg (50 ml and 250 ml)
Number of subjects: 24
Study: 22926600

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 18455908

Group type: EXPERIMENTAL
Intervention: rTMS (1Hz) with exposure therapy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham (placebo) with exposure therapy
Number of subjects: 9
Study: 17485893

Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride (15 mg or 30 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Glibenclamide (1.25 mg or 2.5 mg)
Number of subjects: 46
Study: 15001191

Group type: EXPERIMENTAL
Intervention: 5 mg olmesartan
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg olmesartan
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg olmesartan
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: olmesartan (all doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 11260006

Group type: EXPERIMENTAL
Intervention: F6‐1,25(OH)2D3 (5 microg in 0.1 g of petrolatum)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (0.1 g of petrolatum)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: F6‐1,25(OH)2D3 (50 microg g‐1 of petrolatum) applied to all lesions
Number of subjects: 15
Study: 9732338

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 1148
Study: 7999600

Group type: EXPERIMENTAL
Intervention: Betamethasone 17-valerate solution (1 mg/ml)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Calcipotriol solution (50 micrograms/ml)
Number of subjects: 474
Study: 3189725

Group type: EXPERIMENTAL
Intervention: Allergen extracts from manufacturer A
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Allergen extracts from manufacturer B
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Allergen extracts from manufacturer C
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Allergen extracts from manufacturer D
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: RAST (Pharmacia) and EAST (Kallestad) tests
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Content of major allergens in extracts
Number of subjects: 29
Study: 31325822

Group type: EXPERIMENTAL
Intervention: Multicomponent cognitive-behavioral therapy (adapted for lower socioeconomic groups or standard) + 8 weeks of nicotine patches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smokers with no history of SUDs
Number of subjects: 0
Study: 28086872

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 80
Study: 26111351

Group type: EXPERIMENTAL
Intervention: Prostvac-VF vaccine followed by docetaxel chemotherapy (Arm A, n = 6)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Docetaxel chemotherapy alone (Arm B, n = 2)
Number of subjects: 10